Skip to main content
Quest Diagnostics

Estimated Hepatitis C Prevalence and Viral Clearance Using Residual Sera From a Large Commercial Laboratory-November 2023–September 2024

Estimated Hepatitis C Prevalence and Viral Clearance Using Residual Sera From a Large Commercial Laboratory-November 2023–September 2024

Authors: Hofmeister MG, Symum H, Swanson BE, Barker LK, Zhong Y, Kaufman HW, Thompson WW, Meyer WA 3rd, Gupta N

Citation: Clin Infect Dis. 2026 Jan 8:ciag007. doi: 10.1093/cid/ciag007. Online ahead of print.

Specialties: Infectious disease

Related content

Test FAQ
Hepatitis C Virus Antibody and RNA Testing
Audio Podcast
Screening is the First Line of Defense: Testing for Hepatitis B, Hepatitis C, & HIV
Test FAQ
Hepatitis C Viral RNA, Genotype
On-Demand Webinar
Comprehensive Liver Disease Risk Assessment in Primary Care: Identifying MASLD and Viral Hepatitis
Publication
Social Determinants of Hepatitis C Virus Infection in the United States, 2016–2021
Publication
Hepatitis C virus clearance cascade — United States, 2013–2022
Publication
Hepatitis C Virus Testing, Infection, and Cases Reported Through Public Health Surveillance During Expanded Screening Recommendations, United States, 2013-2021
Test FAQ
Hepatitis C Viral RNA Genotype 3 NS5A Drug Resistance

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.